tradingkey.logo

Catalyst Pharmaceuticals Inc

CPRX
24.350USD
-0.100-0.41%
Fechamento 12/26, 16:00ETCotações atrasadas em 15 min
3.00BValor de mercado
13.59P/L TTM

Catalyst Pharmaceuticals Inc

24.350
-0.100-0.41%

Mais detalhes de Catalyst Pharmaceuticals Inc Empresa

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.

Informações de Catalyst Pharmaceuticals Inc

Código da empresaCPRX
Nome da EmpresaCatalyst Pharmaceuticals Inc
Data de listagemNov 08, 2006
CEODaly (Richard J)
Número de funcionários181
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 08
Endereço355 Alhambra Circle
CidadeCORAL GABLES
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33134
Telefone13055292522
Sitehttps://catalystpharma.com/
Código da empresaCPRX
Data de listagemNov 08, 2006
CEODaly (Richard J)

Executivos da empresa Catalyst Pharmaceuticals Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.15M
-3.07%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
1.08M
+1.11%
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
497.44K
+0.28%
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
381.98K
+0.37%
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
238.93K
+5.35%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
238.46K
+1.83%
Dr. Gary Ingenito, M.D., Ph.D.
Dr. Gary Ingenito, M.D., Ph.D.
Chief Medical Officer and Regulatory Officer
Chief Medical Officer and Regulatory Officer
68.87K
--
Dr. Preethi Sundaram, Ph.D.
Dr. Preethi Sundaram, Ph.D.
Chief Strategy Officer
Chief Strategy Officer
50.51K
+11.44%
Mr. Jeffrey Del Carmen
Mr. Jeffrey Del Carmen
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.51K
+140.01%
Ms. Molly Harper
Ms. Molly Harper
Lead Independent Director
Lead Independent Director
9.11K
+18.37%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.15M
-3.07%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
1.08M
+1.11%
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
497.44K
+0.28%
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
381.98K
+0.37%
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
238.93K
+5.35%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
238.46K
+1.83%

Detalhamento da receita

Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
12.98%
The Vanguard Group, Inc.
7.07%
State Street Investment Management (US)
5.21%
Deerfield Management Company, L.P.
4.05%
McEnany (Patrick James)
3.38%
Outro
67.32%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
12.98%
The Vanguard Group, Inc.
7.07%
State Street Investment Management (US)
5.21%
Deerfield Management Company, L.P.
4.05%
McEnany (Patrick James)
3.38%
Outro
67.32%
Tipos de investidores
Investidores
Proporção
Investment Advisor
44.17%
Investment Advisor/Hedge Fund
27.08%
Hedge Fund
11.03%
Individual Investor
6.07%
Research Firm
2.77%
Pension Fund
1.37%
Bank and Trust
0.51%
Family Office
0.14%
Sovereign Wealth Fund
0.07%
Outro
6.79%

Participação acionária institucional

Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
701
106.95M
89.84%
+15.25K
2025Q3
712
106.95M
90.45%
+1.69M
2025Q2
692
104.76M
87.33%
+3.07M
2025Q1
677
101.32M
86.64%
-4.35M
2024Q4
648
100.17M
86.81%
+1.55M
2024Q3
616
97.42M
88.20%
-1.98M
2024Q2
584
98.72M
96.71%
+772.63K
2024Q1
576
98.03M
86.91%
-4.54M
2023Q4
556
86.46M
95.57%
+3.15M
2023Q3
535
83.30M
96.60%
-1.62M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
16.29M
13.31%
-124.58K
-0.76%
Jun 30, 2025
The Vanguard Group, Inc.
8.74M
7.14%
+268.10K
+3.16%
Jun 30, 2025
State Street Investment Management (US)
5.48M
4.48%
-52.05K
-0.94%
Jun 30, 2025
Deerfield Management Company, L.P.
2.88M
2.35%
-542.67K
-15.86%
Jun 30, 2025
McEnany (Patrick James)
4.28M
3.5%
-200.00K
-4.46%
Jun 09, 2025
Renaissance Technologies LLC
3.25M
2.66%
+295.20K
+9.99%
Jun 30, 2025
Fundsmith LLP
2.71M
2.21%
+557.81K
+25.93%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.87M
2.34%
+101.13K
+3.66%
Jun 30, 2025
American Century Investment Management, Inc.
1.76M
1.44%
+1.23M
+233.86%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.91M
1.56%
-279.90K
-12.80%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Neuroscience and Healthcare ETF
4.37%
Invesco Biotechnology & Genome ETF
3.14%
Invesco S&P SmallCap Health Care ETF
1.5%
Janus Henderson Small Cap Growth Alpha ETF
1.46%
Invesco S&P SmallCap 600 GARP ETF
1.39%
ETC 6 Meridian Small Cap Equity ETF
1.27%
VictoryShares Small Cap Free Cash Flow ETF
1.15%
Invesco S&P SmallCap 600 Pure Growth ETF
1.1%
First Trust Small Cap US Equity Select ETF
1.07%
Cambria Value and Momentum ETF
0.97%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção4.37%
Invesco Biotechnology & Genome ETF
Proporção3.14%
Invesco S&P SmallCap Health Care ETF
Proporção1.5%
Janus Henderson Small Cap Growth Alpha ETF
Proporção1.46%
Invesco S&P SmallCap 600 GARP ETF
Proporção1.39%
ETC 6 Meridian Small Cap Equity ETF
Proporção1.27%
VictoryShares Small Cap Free Cash Flow ETF
Proporção1.15%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção1.1%
First Trust Small Cap US Equity Select ETF
Proporção1.07%
Cambria Value and Momentum ETF
Proporção0.97%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados

Perguntas frequentes

Quem são os cinco principais acionistas de Catalyst Pharmaceuticals Inc?

Os cinco principais acionistas de Catalyst Pharmaceuticals Inc são:
BlackRock Institutional Trust Company, N.A. detém 16.29M Ações, representando 13.31% do total de Ações.
The Vanguard Group, Inc. detém 8.74M Ações, representando 7.14% do total de Ações.
State Street Investment Management (US) detém 5.48M Ações, representando 4.48% do total de Ações.
Deerfield Management Company, L.P. detém 2.88M Ações, representando 2.35% do total de Ações.
McEnany (Patrick James) detém 4.28M Ações, representando 3.50% do total de Ações.

Quais são os três principais tipos de acionistas de Catalyst Pharmaceuticals Inc?

Os três principais tipos de acionistas da Catalyst Pharmaceuticals Inc são:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)

Quantas instituições possuem ações da Catalyst Pharmaceuticals Inc (CPRX)?

Em 2025Q4, 701 instituições possuíam ações da Catalyst Pharmaceuticals Inc, com valor de mercado aproximado de 106.95M, representando 89.84% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em -0.61%.

Qual é a maior fonte de receita da Catalyst Pharmaceuticals Inc?

Em --, o segmento de negócios -- gerou a maior receita para Catalyst Pharmaceuticals Inc, totalizando -- e representando --% da receita total.
KeyAI